Overview
Patients exploring ketamine therapy quickly encounter two distinct options: generic ketamine used off-label, and Spravato (esketamine), the FDA-approved nasal spray. Despite sharing a chemical relationship — esketamine is the S-enantiomer of the ketamine molecule — these two treatments differ in important ways that affect cost, access, treatment experience, and insurance coverage.
Understanding the distinction between these options is essential for making an informed treatment decision and having a productive conversation with your provider. For a broader overview of all administration routes, see our comparison of IV, oral, and nasal ketamine.
The Chemistry: Racemic vs Esketamine
Generic ketamine is racemic, meaning it contains equal parts of two mirror-image molecular forms: S-ketamine and R-ketamine. Both enantiomers have biological activity, though they interact differently with brain receptors. S-ketamine (esketamine) has approximately four times the binding affinity for NMDA receptors compared to R-ketamine and is considered the more potent of the two enantiomers.
Spravato contains only the S-enantiomer (esketamine). Some researchers have suggested that the R-enantiomer may contribute unique therapeutic effects through different receptor pathways, which would give racemic ketamine a broader mechanism of action. This remains an active area of investigation, and the clinical significance of the difference is not yet fully established.
FDA Approval Status
Spravato
Spravato was approved by the FDA in March 2019 specifically for treatment-resistant depression in adults, and later received additional approval for major depressive disorder with acute suicidal ideation or behavior. This FDA approval means:
- Spravato has undergone rigorous phase 3 clinical trials
- Its dosing protocol is standardized
- It is subject to a Risk Evaluation and Mitigation Strategy (REMS) program
- It must be administered at certified healthcare facilities
- Patients must be monitored for at least two hours after each dose
- It has a defined regulatory pathway for insurance coverage
Generic Ketamine
Generic ketamine is FDA-approved only as an anesthetic. Its use for depression, anxiety, PTSD, and other psychiatric conditions is off-label — meaning physicians prescribe it for purposes outside its formal FDA indication. Off-label use is legal and common in medicine (roughly 20 percent of all prescriptions in the US are off-label), but it means:
- There is no standardized protocol mandated by the FDA
- Treatment protocols vary between providers
- Insurance coverage is more difficult to obtain
- The regulatory framework is less defined
Effectiveness
Generic Ketamine
Racemic IV ketamine has been studied in hundreds of clinical trials since the landmark 2000 study by Berman et al. Response rates for treatment-resistant depression consistently range from 60 to 70 percent. The evidence base spans more than two decades and includes multiple routes of administration (IV, IM, sublingual, oral). Many clinicians consider IV racemic ketamine to have the most robust overall evidence base for depression treatment.
Spravato
Spravato's FDA approval was based on multiple phase 3 clinical trials demonstrating its efficacy for treatment-resistant depression. Response rates in the pivotal trials were statistically significant compared to placebo, though some clinicians note that the effect sizes in the phase 3 trials were somewhat more modest than those observed in earlier racemic ketamine studies. Spravato has also demonstrated efficacy in reducing suicidal ideation in the acute setting.
Head-to-Head Comparisons
Direct head-to-head comparisons between racemic ketamine and esketamine are limited but growing. Available data suggests broadly comparable efficacy, with some studies showing a slight advantage for racemic IV ketamine and others showing no significant difference. The question is unlikely to be definitively settled without large, well-designed comparative trials.
Administration and Treatment Experience
Generic Ketamine
| Route | Setting | Duration | Frequency |
|---|---|---|---|
| IV infusion | Clinic | 40–60 min + recovery | 6 sessions over 2–3 weeks, then maintenance |
| IM injection | Clinic | 45–75 min total | Varies by protocol |
| Sublingual | Home or clinic | 60–90 min | 1–3x weekly |
| Oral | Home or clinic | 60–120 min | Varies by protocol |
Generic ketamine offers the greatest flexibility in how treatment is delivered. Providers can choose the route, dose, and schedule that best suits each individual patient.
Spravato
Spravato is administered as a nasal spray in a certified healthcare facility under the REMS program. The patient self-administers the spray under clinical supervision, then remains at the facility for a mandatory two-hour observation period. Treatment sessions occur twice weekly for the first month, then weekly for the second month, then weekly or biweekly during maintenance.
The treatment experience involves:
- Arriving at the certified facility
- Vital sign assessment
- Self-administering the nasal spray (under supervision)
- Resting under observation for two hours while blood pressure and mental status are monitored
- Being cleared to leave (with arranged transportation)
Cost and Insurance
Generic Ketamine
| Factor | Details |
|---|---|
| Per-session cost | $400–$800 (IV), $150–$400/month (sublingual) |
| Insurance coverage | Rarely covered |
| Payment | Out-of-pocket, HSA/FSA eligible |
| Financial assistance | Payment plans at some clinics |
Spravato
| Factor | Details |
|---|---|
| List price | $590–$885 per session (before insurance) |
| Insurance coverage | Often partially covered with prior authorization |
| Typical copay | $0–$250 per session (with insurance) |
| Patient assistance | Janssen CarePath savings program available |
| Without insurance | $600–$900 per session |
The insurance dynamic creates an interesting reversal: while Spravato has a higher list price than most generic ketamine treatments, the availability of insurance coverage can make it less expensive out-of-pocket for patients with qualifying insurance plans. For patients without insurance, generic ketamine — particularly sublingual programs — is typically more affordable. Our detailed cost breakdown covers the full financial picture.
Access and Availability
Generic Ketamine
Generic ketamine clinics exist in most metropolitan areas, and telehealth sublingual programs are available nationwide. Because generic ketamine is not subject to REMS restrictions, providers have more flexibility in how and where they deliver treatment.
Spravato
Spravato can only be administered at healthcare facilities that are certified under the Spravato REMS program. While the number of certified facilities has grown substantially since 2019, availability may be limited in rural areas. The mandatory two-hour observation period after each session also creates practical constraints.
Safety Considerations
Both racemic ketamine and esketamine share similar side effect profiles:
- Dissociation
- Dizziness and sedation
- Nausea
- Increased blood pressure
- Headache
Spravato's REMS program mandates specific safety protocols, including vital sign monitoring and the two-hour observation period. Generic ketamine clinics implement their own safety protocols, which vary in rigor. The quality of safety monitoring depends more on the individual provider than on the medication itself. Learn more about evaluating provider credentials to ensure you receive safe treatment regardless of which formulation you choose.
Which Should You Choose?
Generic ketamine may be the better option if:
- You prefer IV administration for its higher bioavailability
- You want more flexibility in dosing and treatment schedule
- You do not have insurance that covers Spravato
- You prefer at-home sublingual treatment for convenience and cost
- Your provider recommends racemic ketamine based on your specific presentation
Spravato may be the better option if:
- You have insurance that covers Spravato with a manageable copay
- You value the standardized FDA-approved protocol and REMS safety oversight
- You prefer a nasal spray to IV access or sublingual administration
- Your insurance requires you to try the FDA-approved option before covering alternatives
- You want the assurance of FDA regulatory oversight
References
- FDA approves new nasal spray medication for treatment-resistant depression. U.S. Food & Drug Administration, 2019. — FDA approval announcement for Spravato
- Bahji A, et al. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Journal of Affective Disorders, 2021. — Head-to-head comparative analysis of racemic ketamine vs esketamine
- Papakostas GI, et al. S-ketamine vs racemic ketamine: a systematic review. Molecular Psychiatry, 2024. — Review comparing clinical outcomes of the two formulations
- Spravato (esketamine) REMS program. Janssen Pharmaceuticals. — Official REMS program information and certified facility requirements
- Zarate CA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant depression. Archives of General Psychiatry, 2006. — Foundational evidence for racemic ketamine in treatment-resistant depression
Verdict
Generic ketamine offers greater flexibility in dosing and administration routes, often at a lower out-of-pocket cost, and has a longer clinical track record in off-label use. Spravato's FDA approval provides a standardized protocol, regulatory oversight, and a clearer pathway to insurance coverage — though actual insurance costs vary. Neither is definitively superior in effectiveness; the best choice depends on your insurance situation, access to certified facilities, and provider recommendation.